Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme

Radiother Oncol. 2011 Oct;101(1):127-31. doi: 10.1016/j.radonc.2011.06.024. Epub 2011 Jul 19.

Abstract

Purpose: To analyze, whether higher tumor levels of DNA repair enzymes contribute to worse treatment results of glioblastoma multiforme (GBM) patients after postoperative radiotherapy.

Materials and methods: Thirty four patients with GBM received postoperative radiotherapy. Tumor sections were examined for poly-ADP ribose polymerase-1 (PARP-1) and DNA protein kinase (DNA-PK) expression. Immunohistochemical staining intensities of PARP-1 and DNA-PK were determined (score 0-3) and expression levels were correlated with patients overall survival.

Results: Median survival time of the whole study group was 10.0 months (95% CI 8.1-11.9). Median survival of patients with high and low (≥median and <median) tumor PARP-1 levels were 10.0 months (95% CI 7.9-12.1) and 12.0 months (95% CI 8.3-15.7), respectively (p=0.93). In contrast, median survival of patients with high and low tumor DNA-PK levels were 9.0 months (95% CI 7.2-10.8) and 13.0 months (95% CI 10.7-15.3), respectively (p=0.02). In multivariate analysis, DNA-PK expression emerged as a significant independent predictor for overall survival (HR 3.9, 95% CI 1.5-10.7, p=0.01).

Conclusion: This hypothesis generating study showed that high tumor levels of DNA-PK correlate with poor survival of GBM patients. Further studies are needed to confirm these results and to clarify whether DNA-PK inhibitors might have a potential to radiosensitize GBM and improve the treatment outcome of this devastating disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / mortality*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Calcium-Binding Proteins / metabolism*
  • Cohort Studies
  • Combined Modality Therapy
  • Confidence Intervals
  • Dose Fractionation, Radiation
  • Female
  • Gene Expression Regulation, Neoplastic
  • Glioblastoma / genetics*
  • Glioblastoma / mortality*
  • Glioblastoma / pathology
  • Glioblastoma / therapy
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasm Staging
  • Neurosurgical Procedures / methods
  • Poly(ADP-ribose) Polymerases / genetics
  • Poly(ADP-ribose) Polymerases / metabolism*
  • Prognosis
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Sensitivity and Specificity
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • CIB1 protein, human
  • Calcium-Binding Proteins
  • Poly(ADP-ribose) Polymerases